210 related articles for article (PubMed ID: 35998003)
61. Dabrafenib for the treatment of melanoma.
Amaria RN; Kim KB
Expert Opin Pharmacother; 2014 May; 15(7):1043-50. PubMed ID: 24720932
[TBL] [Abstract][Full Text] [Related]
62. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Long GV; Trefzer U; Davies MA; Kefford RF; Ascierto PA; Chapman PB; Puzanov I; Hauschild A; Robert C; Algazi A; Mortier L; Tawbi H; Wilhelm T; Zimmer L; Switzky J; Swann S; Martin AM; Guckert M; Goodman V; Streit M; Kirkwood JM; Schadendorf D
Lancet Oncol; 2012 Nov; 13(11):1087-95. PubMed ID: 23051966
[TBL] [Abstract][Full Text] [Related]
63. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
[TBL] [Abstract][Full Text] [Related]
64. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
65. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Syeda MM; Wiggins JM; Corless BC; Long GV; Flaherty KT; Schadendorf D; Nathan PD; Robert C; Ribas A; Davies MA; Grob JJ; Gasal E; Squires M; Marker M; Garrett J; Brase JC; Polsky D
Lancet Oncol; 2021 Mar; 22(3):370-380. PubMed ID: 33587894
[TBL] [Abstract][Full Text] [Related]
66. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A
Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930
[TBL] [Abstract][Full Text] [Related]
67. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
68. Development of a prognostic Neutrophil Extracellular Traps related lncRNA signature for soft tissue sarcoma using machine learning.
Liu B; He S; Li C; Li Z; Feng C; Wang H; Tu C; Li Z
Front Immunol; 2023; 14():1321616. PubMed ID: 38264665
[TBL] [Abstract][Full Text] [Related]
69. Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?
Gibney GT; Atkins MB
Clin Adv Hematol Oncol; 2015 Jul; 13(7):451-8. PubMed ID: 26353041
[TBL] [Abstract][Full Text] [Related]
70. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
Luke JJ; Hodi FS
Oncologist; 2013 Jun; 18(6):717-25. PubMed ID: 23709751
[TBL] [Abstract][Full Text] [Related]
71. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
72. Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer.
Wang L; Liu Z; Liang R; Wang W; Zhu R; Li J; Xing Z; Weng S; Han X; Sun YL
Elife; 2022 Oct; 11():. PubMed ID: 36282174
[TBL] [Abstract][Full Text] [Related]
73. Dabrafenib: first global approval.
Ballantyne AD; Garnock-Jones KP
Drugs; 2013 Aug; 73(12):1367-76. PubMed ID: 23881668
[TBL] [Abstract][Full Text] [Related]
74. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P; Gutzmer R; Ascierto PA; Maio M; Grob JJ; Murawa P; Dreno B; Ross M; Weber J; Hauschild A; Rutkowski P; Testori A; Levchenko E; Enk A; Misery L; Vanden Abeele C; Vojtek I; Peeters O; Brichard VG; Therasse P
Ann Oncol; 2016 Oct; 27(10):1947-53. PubMed ID: 27502712
[TBL] [Abstract][Full Text] [Related]
75. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.
Spain L; Julve M; Larkin J
Expert Opin Pharmacother; 2016; 17(7):1031-8. PubMed ID: 27027150
[TBL] [Abstract][Full Text] [Related]
76. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.
Feng Q; Huang Z; Song L; Wang L; Lu H; Wu L
Eur J Med Res; 2023 Aug; 28(1):306. PubMed ID: 37649103
[TBL] [Abstract][Full Text] [Related]
77. A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.
Yao K; Zhou E; Cheng C
Cancer Med; 2022 Feb; 11(4):1232-1243. PubMed ID: 35044091
[TBL] [Abstract][Full Text] [Related]
78. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
79. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
80. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]